<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961334</url>
  </required_header>
  <id_info>
    <org_study_id>MOSES</org_study_id>
    <nct_id>NCT03961334</nct_id>
  </id_info>
  <brief_title>MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention</brief_title>
  <acronym>MOSES</acronym>
  <official_title>MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial is addressing the question if a biologically distinct subgroup of ischemic
      stroke patients without known atrial fibrillation at admission, selected by a cut-off level
      of MRproANP concentration, which represents a underlying increased risk of cardiac
      thrombogenicity, benefits from direct oral anticoagulation (DOAC) versus antiplatelets as
      preventive treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three DOACs with marketing authorisation in Switzerland and the EU for the prevention of
      stroke and systemic embolism in patients with atrial fibrillation can be used. Eligible
      patients will be randomly assigned to either the control (antiplatelet) or the experimental
      (DOAC) arm with a ratio of 1:1. Each study participant will be observed during a follow up
      period within one year after index stroke.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent stroke of any type</measure>
    <time_frame>within one year after index stroke</time_frame>
    <description>The primary outcome measure is the time to any recurrent stroke (ischemic, hemorrhagic, unspecified, or fatal stroke)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of major bleeding, recurrent stroke and/or vascular death</measure>
    <time_frame>within one year after index stroke</time_frame>
    <description>Composite of major bleeding, recurrent stroke and/or vascular death (whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding, recurrent stroke and/or vascular death as single components</measure>
    <time_frame>within one year after index stroke</time_frame>
    <description>Each single component of the composite in outcome 2 (major bleeding, recurrent stroke and/or vascular death)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">590</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>DOACs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Direct oral anticoagulants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiplatelets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiplatelets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>20mg 1x/d</description>
    <arm_group_label>DOACs</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>150mg 2x/d</description>
    <arm_group_label>DOACs</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>5mg 2x/d</description>
    <arm_group_label>DOACs</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>60mg 1x/d</description>
    <arm_group_label>DOACs</arm_group_label>
    <other_name>Lixiana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>100mg 1x/d</description>
    <arm_group_label>Antiplatelets</arm_group_label>
    <other_name>Aspirin cardio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>75mg 1x/d</description>
    <arm_group_label>Antiplatelets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of ischemic stroke

          -  elevated MRproANP level within 24 hours from symptom onset

          -  Age ≥ 18 years

          -  Signed informed consent

        Exclusion Criteria:

          -  History of AF, AF on 12-lead ECG on admission or any AF ≥30 seconds during
             heart-rhythm monitoring prior to randomization

          -  Other condition that require anticoagulant therapy (e.g., venous thromboembolism) as
             per Investigator's judgment including therapeutical dose of low-molecular-weight
             heparin or heparin

          -  Strong likelihood to be treated with prolonged (i.e. more than 30 days) dual
             antiplatelet therapy during the course of the trial (such as coronary stenting, etc.)

          -  Patients undergoing planned procedures where therapy with a DOAC is a contraindication
             (e.g. surgery)

          -  Previous intracranial hemorrhage in the last year

          -  Evidence of severe cerebral amyloid angiopathy if MRI scan performed

          -  Chronic kidney disease with creatinin clearance &lt;30ml/min and or subject who requires
             haemodialysis or peritoneal dialysis

          -  Known bleeding diathesis (e.g. active peptic ulcer disease , platelet count &lt;
             100'000/mm3 or haemoglobin &lt; 9 g/dl or INR ≥ 1.7, documented haemorrhagic tendencies
             or blood dyscrasias)

          -  Active infective endocarditis

          -  CT or MRI evidence of cerebral vasculitis

          -  Known allergy or intolerance to antiplatelets or DOACs

          -  Female who is pregnant or lactating or has a positive pregnancy test at time of
             admission

          -  Current participation in another drug trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mira Katan, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mira Katan, PD Dr. med.</last_name>
    <phone>+41 44 255 47 32</phone>
    <email>mira.katan@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Götz Thomalla, MD</last_name>
      <email>thomalla@uke.de</email>
    </contact>
    <investigator>
      <last_name>Götz Thomalla, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital - Ullevål</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Else Charlotte Sandset, Dr. med.</last_name>
      <email>else@sandset.net</email>
    </contact>
    <investigator>
      <last_name>Else Charlotte Sandset, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joan Montaner, MD</last_name>
      <email>jmontaner-ibis@us.es</email>
    </contact>
    <investigator>
      <last_name>Joan Montaner, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joan Montaner, MD</last_name>
      <email>jmontaner-ibis@us.es</email>
    </contact>
    <investigator>
      <last_name>Joan Montaner, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Campus Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joan Montaner, MD</last_name>
      <email>jmontaner-ibis@us.es</email>
    </contact>
    <investigator>
      <last_name>Joan Montaner, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau, Department of Neurology</name>
      <address>
        <city>Aarau</city>
        <state>Argau</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timo Kahles, MD</last_name>
      <email>timo.kahles@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Timo Kahles, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Marco De Marchis, MD</last_name>
      <email>gian.demarchis@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Gian Marco De Marchis, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bern/Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urs Fischer, MD</last_name>
      <email>urs.fischer@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Urs Fischer, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>St.Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Zurich, Department of Neurology</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mira Katan, PD Dr. med.</last_name>
      <email>mira.katan@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Mira Katan, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesse Dawson, MD</last_name>
      <email>jesse.dawson@glasgow.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Jesse Dawson, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Mira Katan</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

